Copenhagen based FluoGuide is working to light up tumors for surgeons by guiding fluorescent molecules to uPAR - a target that has been studied widely in Scandinavia

blonca9
Oct 11, 2024
1 min read

CEO Morten Albrechtsen describes the rational for this target for this purpose and how they FluoGuide has designed its fluorescent agent. The company is currently focused on brain, head & neck, and lung cancer.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Copenhagen based FluoGuide is working to light up tumors for surgeons by guiding fluorescent molecules to uPAR - a target that has been studied widely in Scandinavia

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight